Staff Reporter
,
Hong Kong
Photo from Envato
However, competition from neighbouring markets poses downside risks.
Hong Kong’s pharmaceutical market is projected to reach $3b by 2028 at a compound annual growth rate of 8.1% in US dollar terms.
A BMI report said that Hong Kong will remain attractive for clinical trials, supporting the pharmaceutical sector’s expansion.
On 21 November, authorities announced the opening of the Greater Bay Area International Clinical Trial Institute in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone.
The institute will feature a biobank, managed by the Hospital Authority and the Chinese University of Hong Kong, capable of storing over 400,000 biological samples.
However, Hong Kong’s small population size and competition from neighbouring markets such as Mainland China and South Korea pose downside risks.
These regions already have well-established clinical trial infrastructures and global networks, which may divert investment away from Hong Kong.
Join
Healthcare Asia Magazine
community
Since you’re here…
…there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.
We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.
Let us help you drive your business forward with a good partnership!
